We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Testosterone Level Linked to SIDS

By HospiMedica staff writers
Posted on 07 Dec 2005
In a new study, a postmortem blood analysis showed that male babies who died of sudden infant death syndrome (SIDS) had testosterone levels that were much higher than those of control babies.

The study involved 127 SIDS autopsies and 42 controls. More...
The SIDS males had testosterone levels that were 120% higher than the male controls. Testosterone levels in female SIDS babies were 50% higher than the female controls. Estradiol levels, on the other hand, were not significant in either group. The findings were reported in the November 2005 issue of the Journal of Pediatrics.

The authors noted that earlier evidence in animal models and human studies had suggested that elevated testosterone levels may be linked to breathing that is depressed in sleep.

"Testosterone administration decreases ventilation and ventilatory drive during sleep in adult humans and infant primates,” wrote Michael J. Emery, Ph.D., of the University of Washington (Seattle, USA; www.washington.edu), and colleagues, "and increased androgen levels are associated with sleep-disordered breathing in human adult males and females.” These results might explain a mechanism to a condition with no known biologic cause, they said.

The authors also noted that there is "a striking coincidence” between postnatal rises in the sex hormones and the age range of risk for SIDS, with both peaking between one and five months of age. They acknowledged that their study sample was small and that more research is needed to understand the relationship between high testosterone and SIDS.




Related Links:
University of Washington

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.